anti-CD38 mAb (Crucell)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameanti-CD38 mAb (Crucell)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionLymphocyte differentiation antigen CD38 inhibitors
TargetsLymphocyte differentiation antigen CD38
Therapy Area/IndicationsColonic NeoplasmsMultiple MyelomaLymphoma, Non-Hodgkin
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNetherlands
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesCrucell NV
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCrucell NV
Active IndicationsN/A
Inactive IndicationsColonic NeoplasmsMultiple MyelomaLymphoma, Non-Hodgkin

Other Information

ATC CodeN/A
Related LinksN/A